What's not to love about Celgene earnings?
Celgene (CELG) turned in a quarter that beat analyst expectations on the top and bottom lines, with revenue up 17% year-over-year and adjusted EPS up 18% year-over-year, yet the market didn't appear too impressed (the stock sold off about 3% today).
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson dive into the key takeaways from earnings.
David Williamson has no position in any stocks mentioned. Michael Douglass owns shares of Celgene. The Motley Fool recommends Celgene. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
